For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- JPMA to Propose New NHI Drug Price System: JPMA President
January 21, 2002
- OTC NEWS IN BRIEF
January 21, 2002
- Drug Misuse Cases Reach 108 in 2000 with 12 Requiring Hospitalization
January 21, 2002
- Merck Hoei Aiming at Becoming No. 1 Generic House
January 21, 2002
- Private Advisory Board to Mull Medical Fee System to Be Set Up: Health Minister Sakaguchi
January 21, 2002
- BUSINESS NEWS IN BRIEF
January 21, 2002
- Toxicogenomics, Nanotechnology Stressed in 2002 Korosho Budget Requests
January 21, 2002
- Kyowa Hakko Succeeds in Producing Antibodies with High ADCC
January 21, 2002
- Wholesalers Environment to Be Tougher This Year: EAD Director
January 21, 2002
- First Survey on Diabetic Neuropathy Conducted in Japan: JPA
January 21, 2002
- NHI Price System Reform to Give Incentives to New Drugs: PFSB Director General
January 21, 2002
- Korosho Starts Research to Clarify Causes of 3 Severe ADRs
January 21, 2002
- Birth Rate Lowest Ever Recorded, Continuing Trend of Fewer Children
January 21, 2002
- University of Tokyo to Abolish Master Degree System
January 21, 2002
- Olympus ProMarketing: Semiconductor Laser Device
January 14, 2002
- Roche Was Selected to Strengthen R&D Ability: Mr Nagayama of Chugai
January 14, 2002
- Shimadzu: Floor-Mounted Type Angiographic C-arm Support MH-300
January 14, 2002
- Dainippon Joins Tsumura in Development of Ca Antagonist
January 14, 2002
- Princeton Note Litigation Settled
January 14, 2002
- ATOL-MI Transferred to Yamashita Ikakiki
January 14, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…